Trial reportEye (London, England)2023
Bifocal use in hyperopic anisometropic amblyopia treated with atropine: a proof-of-concept randomized trial.
Trial report in Eye (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- The Changing Natural History of Anisometropia: A Scoping Review.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Article
- Systematic Review and Meta-Analysis of RCTs on Efficacy of Conventional vs. Emerging Treatments for Amblyopia.Life (Basel, Switzerland) · 2026Review
- Non-surgical treatment of strabismus in children: a review of recent advances.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the effect of bifocal wearing in the amblyopic eye when atropine is used in the sound eye for the treatment of hyperopic anisometropic amblyopia.
methodsChildren 4-8 years old were randomly assigned to bifocal + atropine (n = 16) or only atropine (control, n = 19) groups of treatment in a proof-of-concept study. Measurements included visual acuity (logMAR), prism and cover test, stereoacuity (Randot preschool or Randot circles), contrast sensitivity (MARS test), accommodation (Grand Seiko WAM5500 and dynamic retinoscopy), retinoscopic and subjective refraction, before starting treatment and at 6 months, except accommodation, which was remeasured at 9-11 months. Main outcome measure was change in logMAR lines of visual acuity, and secondary outcome measures were change in stereoacuity and contrast sensitivity in the amblyopic eye, at 6 months.
resultsImprovement in visual acuity of the amblyopic eye was significantly better (p = 0.04) in the atropine plus bifocal (3.3 ± 0.9 logMAR lines) than in the atropine only group (2.6 ± 0.8 logMAR lines), whereas change in stereoacuity and contrast sensitivity was not significantly different between the two groups. Differences in accommodative gain, which was impaired in the amblyopic compared to the sound eye, before treatment, decreased after treatment, in the atropine group (0.62 ± 0.16 vs 0.79 ± 0.2, p = 0.3), and atropine + bifocal group (0.69 ± 0.15 vs 0.82 ± 0.2, p = 0.4).
conclusionsUse of bifocal lens add in the amblyopic eye of children with hyperopic anisometropic amblyopia, treated by atropine penalization, is beneficial in the follow-up period of 6 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.